High-dose glucose-insulin-potassium has hemodynamic benefits and can improve cardiac remodeling in acute myocardial infarction treated with primary Percutaneous coronary intervention: From a randomized controlled study

Heart Center, Beijing Chaoyang Hospital and Institute of Cardiovascular Disease, Capital Medical University, Beijing - 100020, P. R. China.
Journal of cardiovascular disease research 07/2010; 1(3):104-9. DOI: 10.4103/0975-3583.70899
Source: PubMed


To evaluate the effects of high-dose glucose-insulin-potassium (GIK) solution on hemodynamics and cardiac remodeling in patients with acute myocardial infarction (AMI) treated with primary percutaneous coronary intervention (PCI).
We observed the changes in the hemodynamic parameters in 26 patients with AMI. All patients received primary PCI before entering the study. All patients in the study were randomized into the GIK group (n = 14) or the control group (n = 12). Patients in the GIK group received high-dose GIK solution (25% glucose, 80 mmol/L KCl and 50 IU/L insulin; 1.5 ml/kg/h) over 24 h. Patients in the control group received standard therapy. We monitored the hemodynamic parameters at baseline and after 6 h, 12 h, 18 h and 24 h, respectively. Then, we followed-up the cardiac function with echocardiography after 7 days, 1 month and 6 months.
The basic clinical data was similar between the groups. Primary PCI was performed successfully in 25 patients. The two groups were indistinguishable in all factors measured. GIK solution did not have a deleterious effect on the hemodynamic parameters. The pulmonary capillary wedge pressure increased during the first 12-h period and then decreased smoothly (F = 3.75, P = 0.02). The trends were similar between the two groups. The system vascular resistance index (SVRI) and pulmonary vascular resistance index (PVRI) decreased during the first 12 h in the GIK group but increased in the control group. The GIK solution significantly influenced SVRI (F = 4.71, P = 0.02). GIK solution improved the cardiac function measured by stroke volume (F = 4.11, P = 0.03) and cardiac index (F = 4.40, P = 0.02). In the 6-month follow-up, GIK improved cardiac remodeling (left ventricular diastolic diameter: 49.2 ± 2.89 vs. 53.9 ± 2.48, P < 0.001; left ventricular systolic diameter: 32.9 ± 2.24 vs. 35.9 ± 2.78, P < 0.01).
High-dose GIK solution had no adverse effects on the hemodynamics in AMI patients treated with primary PCI. It can improve cardiac function by lowering SVRI. In the 6-month follow-up, it improved cardiac remodeling.

Full-text preview

Available from: PubMed Central
  • Source
    • "2 80 50 IU/l 25 58.3 64.3 63.2 67 26 12 14 IV 1.5 ml/kg/h Li [25] 3 80 50 IU/l 25 68.3 77 60.5 58.2 274 139 135 IV 1.5 ml/kg/h ECLA pilot trial High dose [26] 3 40 20 IU/l 10 68.3 75.9 60.5 58 272 139 133 IV 1 ml/kg/h ECLA pilot trial Low dose [26] "
    [Show abstract] [Hide abstract]
    ABSTRACT: The purpose of this meta-analysis was to evaluate protective effects of glucose-insulin-potassium (GIK) on outcomes after coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI). We systematically searched Medline/Pubmed, Elsevier, Embase, Web of Knowledge and Google Scholar. A total of 1206 studies were retrieved during the extensive literature search of all major databases; however, 38 trials reporting the end-point of interest were selected. We performed a pooled analysis of outcomes following PCI: incidence of cardiac arrest [odds ratio (OR) of 0.91; 95% confidence interval (CI): 0.76-1.09; P = 0.3], stroke (OR of 1.71; 95% CI: 0.37-1.37; P = 0.3), cardiogenic shock (OR of 1.02; 95% CI: 0.92-1.14; P = 0.6), reinfarction (OR of 0.95; 95% CI: 0.81-1.14; P = 0.5) and mortality (OR of 1.04; 95% CI: 0.96-1.13; P = 0.3); and following CABG: incidence of atrial fibrillation (OR of 0.86; 95% CI: 0.70-1.05; P = 0.1), incidence of ventricular fibrillation (OR of 0.83; 95% CI: 0.62-1.13; P = 0.2), reinfarction (OR of 0.97; 95% CI: 0.74-1.27; P = 0.8), infection (OR of 1.04; 95% CI: 0.67-1.62; P = 0.8), length of intensive care unit stay (LIS) [standard mean differences (SMD) of -0.27; 95% CI: -0.40 to -0.14; P = 0.000], length of hospital stay (LHS) (SMD of -0.035; 95% CI: -0.12 to -0.05; P = 0.4) and mortality (OR of 0.72; 95% CI: 0.41-1.26; P = 0.2). Our results showed that GIK did not have considerable cardioprotective effects. However, patients undergoing CABG seem to be better responders to GIK therapy compared with patients undergoing PCI. Furthermore, in contrast to CABG, GIK therapy in patients undergoing PCI might be associated with more complications rather than protective effects. © The Author 2015. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.
    Interactive Cardiovascular and Thoracic Surgery 08/2015; DOI:10.1093/icvts/ivv222 · 1.16 Impact Factor

  • The Journal of Clinical Endocrinology and Metabolism 05/2011; 96(5):1272-5. DOI:10.1210/jc.2011-0683 · 6.21 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Reliving the stress of the urban public transport, the metro system is greatly superior to other transport methods on the load, energy consumption, mean drive speed, arrival on time and comfortableness. The passengers comfortable is the important part for developing the train operation strategies. For optimization of the energy, time saving and the passengers comfortableness during operation of the train, the proper objective function is designed. The train operation strategy for meeting the inter-stop passengers comfortableness at the curves was developed and the energy and time savings of the section were combined, and the optimization operation plan for the whole line was designed, to better meet the metro train operation.
    09/2011; 328-330:2014-2018. DOI:10.4028/